{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Tumors&page=5", "query": { "condition": "Oral Tumors", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 2228, "total_pages": 223, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Tumors&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Tumors&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T09:17:16.923Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01810913", "title": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2013-03-22", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 338, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01810913" }, { "nct_id": "NCT00641160", "title": "Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonhematologic Malignancies" ], "interventions": [ { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Metronome Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-03", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2008-09-26", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00641160" }, { "nct_id": "NCT05798780", "title": "The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oral Cavity Cancer", "Oropharynx Cancer", "Hypopharynx Cancer", "Larynx Cancer" ], "interventions": [ { "name": "ENHANCE Intervention - Exercise and Nutrition", "type": "BEHAVIORAL" }, { "name": "ENHANCE Intervention - Nutrition Only", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-04-06", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798780" }, { "nct_id": "NCT00467779", "title": "Study of Cobimetinib in Participants With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "cobimetinib", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2007-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-08-26", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 4, "location_summary": "Los Angeles, California • Stanford, California • Detroit, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00467779" }, { "nct_id": "NCT01748942", "title": "Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dysphagia", "Pain", "Stage I Oropharyngeal Squamous Cell Carcinoma", "Stage II Oropharyngeal Squamous Cell Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Transoral Robotic Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2012-12", "completion_date": "2017-03-29", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748942" }, { "nct_id": "NCT05785715", "title": "Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "NX-13 250mg", "type": "DRUG" }, { "name": "NX-13 750mg", "type": "DRUG" }, { "name": "NX-13 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 81, "start_date": "2023-04-24", "completion_date": "2025-05-30", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 11, "location_summary": "Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chesterfield", "state": "Michigan" }, { "city": "Troy", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785715" }, { "nct_id": "NCT05929235", "title": "A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Urothelial Carcinoma", "Oral Drug Administration", "Open Label" ], "interventions": [ { "name": "FX-909", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA ®)", "type": "DRUG" }, { "name": "KEYTRUDA ®( Pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Flare Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2023-08-24", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 12, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05929235" }, { "nct_id": "NCT01693718", "title": "A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "5- Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "59 Years", "maximum_age": null, "sex": "ALL", "summary": "59 Years and older" }, "enrollment_count": 44, "start_date": "2003-03", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01693718" }, { "nct_id": "NCT00003455", "title": "Antineoplaston Therapy in Treating Women With Advanced Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Breast Cancer", "Recurrent Breast Cancer" ], "interventions": [ { "name": "antineoplaston A10", "type": "DRUG" }, { "name": "antineoplaston AS2-1", "type": "DRUG" }, { "name": "alternative product therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "biologically based therapies", "type": "PROCEDURE" }, { "name": "cancer prevention intervention", "type": "PROCEDURE" }, { "name": "complementary and alternative therapy", "type": "PROCEDURE" }, { "name": "differentiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003455" }, { "nct_id": "NCT03537482", "title": "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "APG-2575", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2018-08-07", "completion_date": "2025-02-15", "has_results": false, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-10-05T09:17:16.923Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537482" } ] }